MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study

This article has no abstract
Epistemonikos ID: 99225100bb4c3c6e3e18420616df329ae664e1de
First added on: Feb 12, 2025